PP01.11: Clinical Outcomes of Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients: A Retrospective Study from Bogotá

Simple item page
dc.contributor.authorAndres Felipe Bejarano
dc.contributor.authorNicolás Duque Clavijo
dc.contributor.authorHenry Vargas
dc.contributor.authorErick Cantor
dc.contributor.authorJavier Segovia
dc.contributor.authorLuís Pino
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T19:43:41Z
dc.date.available2026-03-22T19:43:41Z
dc.date.issued2025
dc.identifier.doi10.1016/j.jtho.2025.07.063
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2025.07.063
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/77761
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofJournal of Thoracic Oncology
dc.sourceFundación Santa Fe de Bogotá
dc.subjectMedicine
dc.subjectOsimertinib
dc.subjectLung cancer
dc.subjectOncology
dc.subjectRetrospective cohort study
dc.subjectMutant
dc.subjectInternal medicine
dc.subjectCancer
dc.titlePP01.11: Clinical Outcomes of Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients: A Retrospective Study from Bogotá
dc.typearticle

Files

Collections

Artículo Científico Publicado